Form 4: HealthEquity CEO Jon Kessler Reports Stock Transactions
SEC Form 4 Filing
HealthEquity's CEO, Jon Kessler, reports the vesting of restricted stock units and adjustments to his holdings of common stock and stock options.
Summary
- On March 27, 2024, Jon Kessler, the CEO of HealthEquity, Inc., reported transactions involving the company's stock.
- 103,806 restricted stock units vested, each representing a contingent right to receive one share of HealthEquity's common stock.
- Following the transaction, Kessler directly owns 317,797 shares of common stock.
- Kessler also indirectly owns 126,635 shares of common stock through GKF, LLC.
- He also holds options to buy shares of common stock at prices of $41.28, $61.72 and $73.61.
- Kessler disclaims beneficial ownership of securities held by GKF, LLC, except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: Neutral sentiment as this is a standard regulatory filing of insider transactions.
Positives
- The vesting of restricted stock units suggests confidence in the company's future performance.
Management Comments
- The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Comparison to Industry Standards
- Insider transactions are common across publicly traded companies.
- The size and frequency of these transactions are typical for CEOs of companies of HealthEquity's size.
- Comparable companies such as WageWorks (now part of HealthEquity) and Benefitfocus also have similar insider transaction reporting.
Stakeholder Impact
- Shareholders are informed about the CEO's stock transactions, providing insights into management's perspective on the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of earliest transaction: Vesting of restricted stock units. |
| 03/27/2027 | Expiration date for stock options at $41.28. |
| 03/27/2028 | Expiration date for stock options at $61.72. |
| 03/26/2029 | Expiration date for stock options at $73.61. |
| 03/28/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.